<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180947</url>
  </required_header>
  <id_info>
    <org_study_id>NAVE-CYCLO</org_study_id>
    <nct_id>NCT00180947</nct_id>
  </id_info>
  <brief_title>Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse</brief_title>
  <official_title>Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      This is a phase II study to determine the antitumor activity of Vinorelbine and
      Cyclofosfamide association among patients with refractory tumours or in relapse with
      rhabdomyosarcomas and other soft tissue tumours, Ewing tumours, osteosarcomas, neuroblastomas
      or medulloblastomas.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the antitumor activity of Vinorelbine and oral Cyclofosfamide association in refractory tumours or in relapse</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the hematologic tolerance of this association</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of injectable Vinorelbine</measure>
  </secondary_outcome>
  <enrollment>210</enrollment>
  <condition>Rhabdomyosarcomas</condition>
  <condition>Neoplasms, Connective and Soft Tissue</condition>
  <condition>Ewing Tumor</condition>
  <condition>Osteosarcomas</condition>
  <condition>Neuroblastomas</condition>
  <condition>Medulloblastomas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine, cyclofosfamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 12 months and &lt; 25 years

          -  Measurable disease

          -  Score of Lansky &gt; 30 or World Health Organization (WHO) score &lt; 2

          -  Life expectancy &gt; 2 months

          -  Satisfactory hematologic conditions:

               -  Polynuclear neutrophiles &gt; 1 X 10^9/l.

               -  Platelets &gt; 100 X 10^9/l or &gt; 50 X 10^9 in the event of medullary invasion.

          -  Creatinine &lt; 1.5 of normal for age or clearance &gt; 70 ml/min/1.73 m2

          -  Normal hepatic function:

               -  Bilirubin &lt; 3 N

               -  ASAT and ALAT &lt; 2,5 N).

          -  Absence of toxicity of bodies (Rank &gt; 2 according to coding National Cancer
             Institute-Common Toxicity Criteria [NCI-CTC] version 2.0)

          -  Absence of antecedent of hematuric cystitis to repetition

          -  Written consent, signed by the patient or the two parents or holder(s) of the parental
             authority of the minor subjects

        Exclusion Criteria:

          -  Does not satisfy the criteria of eligibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile OBERLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Odile OBERLIN, MD</last_name>
    <phone>33 1 42 11 41 74</phone>
    <email>oberlin@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annie REY</last_name>
    <phone>01 42 11 41 37</phone>
    <email>rey@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile OBERLIN, MD</last_name>
      <phone>33 1 42 11 41 74</phone>
      <email>oberlin@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Annie REY</last_name>
      <phone>33 1 42 11 41 37</phone>
      <email>rey@igr.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>Soft parts tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neoplasms, Connective and Soft Tissue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

